DSP Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

DSP Healthcare Growth Direct Plan

NAV
₹44.3190
-0.14%
(17 Sep)
AUM
2,934 Cr
TER
0.58%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+71.5%
+65.2%
+64.9%
+58.6%
+56.3%
3Y
+36.7%
+38.8%
+39.0%
+36.9%
+20.8%
5Y
+32.8%
+29.1%
NA
+33.5%
+33.9%
ALL
+18.8%
+13.2%
+32.8%
+19.0%
+29.3%
VOL
19.6%
20.3%
22.8%
18.2%
14.7%
TER
0.8%
0.7%
0.4%
1.2%
0.6%
AUM
₹1,593 Cr
₹4,851 Cr
₹5,946 Cr
₹6,143 Cr
₹2,934 Cr
INFO
0.96
0.65
1.44
1.04
1.99
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
DSP Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Aug
Top holdings
Sun Pharmaceuticals Industries Ltd
11.6%
Suven Pharmaceuticals Ltd
10.1%
Lupin Ltd
8.3%
Cipla Ltd
7.8%
Ipca Laboratories Ltd
7.6%
Alembic Pharmaceuticals Ltd
5.1%
Globus Medical Inc Class A
5.1%
Apollo Hospitals Enterprise Ltd
4.4%
Concord Biotech Ltd
3.5%
Net Receivables/Payables
3.5%
Top industry exposure
Healthcare
91.8%
Financial Services
1.8%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
10%
Lock-in period
-
Exit load
• 0.5% for redemption within 30 days
Fund objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
Fund manager(s)
Chirag Dagli

FAQs